A Multi-country, Prospective, Post-marketing Study of UPadacitinib Evaluating Speed of Onset and Durability of Effectiveness for Patients With Moderate to Severe Crohn's Disease for 3 Years in Real-world Clinical Practice (UPlift)
Latest Information Update: 23 Apr 2025
At a glance
- Drugs Upadacitinib (Primary)
- Indications Crohn's disease
- Focus Therapeutic Use
- Acronyms UPlift
- Sponsors AbbVie
Most Recent Events
- 20 Dec 2024 Planned End Date changed from 30 Sep 2028 to 1 Sep 2028.
- 20 Dec 2024 Planned primary completion date changed from 30 Sep 2028 to 1 Sep 2028.
- 21 Dec 2023 Planned initiation date changed from 15 Aug 2023 to 31 Jan 2024.